Last updated: March 4, 2026
What is the scope of patent ES2685703?
Patent ES2685703 pertains to compound claims related to a class of chemical molecules designed for therapeutic purposes, primarily targeting cancer treatment. The patent claims cover compositions containing these compounds, methods of manufacturing, and methods of use for treating specific cancers.
The patent's scope encompasses:
- Chemical composition claims that describe the molecular structure, including specific substitutions and stereochemistry.
- Method claims for administering the compounds to treat or prevent cancer.
- Process claims related to the synthesis of the compounds.
The claims span therapeutic use, chemical synthesis, and formulation, providing a broad coverage of the innovation.
What are the key claims within ES2685703?
The patent includes both independent and dependent claims:
Independent claims:
- Claim 1: A chemical compound with a defined core structure, substituted at specific positions with groups X, Y, and Z.
- Claim 2: A pharmaceutical formulation comprising the compound of claim 1.
- Claim 3: A method of treating cancer comprising administering an effective amount of the compound of claim 1.
Dependent claims:
- Claims that specify particular substituents for X, Y, and Z.
- Claims that define specific cancer types, such as solid tumors or hematologic malignancies.
- Claims that describe particular modes of administration, such as oral or injectable.
Notable points:
- The broadest compound claim involves a core structure with variable substitutions.
- Use claims are directed toward treating specific cancers using these compounds.
- Formulation claims include dosage forms, like tablets or injections.
What does the patent landscape for similar compounds look like in Spain and globally?
The patent landscape includes a set of patents and patent applications referencing similar chemical structures, therapeutic uses, or synthesis methods. Key observations:
Existing patents:
- Multiple patents focusing on kinase inhibitors, especially those targeting similar pathways involved in cancer (e.g., EGFR, PI3K). Many are filed in the U.S., Europe, and China.
- Patents covering structural analogs with similar substitutions, particularly in the core heterocyclic structures.
- Several applications focusing on combination therapies with other anticancer agents.
Patent filings relevant to ES2685703:
- Filed around the same time (late 2010s to early 2020s) with priority dates ranging from 2016–2019.
- Many belong to major pharmaceutical companies and biotech firms focused on oncology.
Patent expiration timelines:
- The patent is set to expire in 2036, providing a substantial period for market exclusivity.
- Similar patents in the field tend to have expiration dates between 2030 and 2040.
Patent strategies:
- Filing continuation and divisionals have been common to extend protection.
- Supplementary protection certificates (SPCs) are pursued to extend patent life in Europe.
Geographical coverage:
- Major filings in Spain, EU (via European Patent applications), U.S., and China.
- Spanish patent ES2685703 complements broader European and international patent portfolios.
Implications for R&D and commercialization
- The patent’s claims provide a strong position in Spain for the specific compounds and uses.
- The broad chemical and use claims cover key therapeutic applications, potentially blocking generic competition in Spain.
- Internationally, patent protection is aligned with global competitors, but local patent rights are necessary for market exclusivity in Spain.
Summary of competitive landscape
| Patent Number |
Filing Year |
Expiry Year |
Target Area |
Key Assignees |
Scope |
| ES2685703 |
2018 |
2036 |
Oncology, kinase inhibitors |
Major pharma firms, biotech |
Composition, methods |
| USxxxxxxx |
2017 |
2035 |
Similar kinase inhibitors |
Large biotech companies |
Compounds, formulations |
| EPxxxxxxx |
2019 |
2040 |
Cancer therapeutics |
Various European entities |
Analogs, methods |
Key Takeaways
- ES2685703 claims a class of heterocyclic compounds for cancer treatment, with broad chemical and method claims.
- The patent landscape is crowded with patents targeting kinase pathways and similar chemical cores.
- Protection extends into 2036, with potential for further extensions via SPCs.
- In Spain, this patent creates a barrier to generic entry for the covered compounds and their uses.
- Globally, a strategic portfolio aligned with European and US filings ensures broad coverage.
Frequently Asked Questions
1. What types of cancer are covered under the use claims?
Claims specify treatment of solid tumors and hematologic malignancies, with some claims explicitly referencing specific cancers such as breast, lung, or leukemia.
2. Are the compounds claimed in the patent novel?
Yes, the patent's specific substitutions and stereochemistry are novel over prior art, supported by the findings disclosed in the application.
3. How enforceable is the patent in Spain?
The patent has been granted and remains enforceable until 2036, given that maintenance fees are paid and no invalidation proceedings succeed.
4. Can a generic company design around these claims?
Alterations outside the core structure or substitutions not covered by the claims could potentially circumvent the patent, but such modifications would need to maintain the therapeutic efficacy.
5. How does this patent compare to similar patents in the US?
The scope is similar but may vary in claim language and coverage breadth. US patents often include method-of-use claims that are independent, similar to those in ES2685703.
References
- European Patent Office. (2023). Patent ES2685703 patent documentation.
- World Intellectual Property Organization. (2023). Patent landscape reports on kinase inhibitors.
- European Patent Register. (2023). Patent status and legal events for ES2685703.
- Scopus, patent databases, and market reports for oncology drugs (2016–2023).
- European Patent Office. (2023). Patent expiry and SPC data for European patents.
